2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus July 2001: DRAFT

REFERENCES

• CDC. USPHS/IDSA guidelines for the prevention of oppor-tunistic infections in persons infected with human immuno-deficiency virus: A summary. MMWR. 1995;44(No. RR–8).
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recom-mendations. Clin Infect Dis. 1995;21\(suppl 1):S32–S43.
   PubMedGoogle Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus: A summary. Ann Intern Med. 1996;124:348-368.
   Google Scholar
• CDC. USPHS/IDSA guidelines for the prevention of op-portunistic infections in persons infected with human im-munodeficiency virus. MMWR. 1997;46(No. RR–12).
   Google Scholar
• CDC. USPHS/IDSA guidelines for the prevention of op-portunistic infections in persons infected with human im-munodeficiency virus. MMWR. 1999;48(No. RR–10).
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations. Clin Infect Dis. 1997;25\(suppl 3):S313–S315.
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 1999;30\(suppl 1):S1–S93.
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med. 1997;127:922-946.
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus. Am Fam Physician. 1997;56: 823–830,1131–1146,1387–1392.
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus. Am Fam Physician. 2000;61(1):163–171.
   PubMed Web of Science ®Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA report on the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus. Pediatrics. 1998; 102:1064–1085.
   Google Scholar
• Kaplan JE, Masur H, Jaffe HW, Holmes KK. Reducing the impact of opportunistic infections in patients with HIV infection: New guidelines. [Editorial]. JAMA. 1995;274(4):347–348.
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Masur H, Jaffe HW, Holmes KK. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines [Editorial]. JAMA. 1997;278:337–338.
   PubMed Web of Science ®Google Scholar
• CDC. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and guidelines for use of antiretroviral agents in HIV-infected adults and adoles-cents. MMWR. 1998;47 (No. RR–5).
   Google Scholar
• McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, and the Adult/Adolescent Spectrum of Disease Group. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS. 1999;13:1687–1695.
   PubMed Web of Science ®Google Scholar
• USPHS/IDSA Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. http:// www.hivatis.org.
   Google Scholar
• Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18:421.
   PubMed Web of Science ®Google Scholar
• Phair J, Munoz A, Saah A, Detels R, et al, and the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with HIV-1. N Engl J Med. 1990;322:61–65.
   Web of Science ®Google Scholar
• Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: Reassessment of indications for chemoprophylaxis. J Infect Dis. 1998;178:1126–1132.
   PubMed Web of Science ®Google Scholar
• CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immu-nodeficiency virus. MMWR. 1989;38\(suppl 5):1–9.
   PubMedGoogle Scholar
• Bozzette SA, Finkelstein DM, Spector SA, et al. A ran-domized trial of three antipneumocystis agents in pa-tients with advanced human immunodeficiency virus in-fection. N Engl J Med. 1995;332:693–699.
   PubMed Web of Science ®Google Scholar
• Schneider MME, Hoepelman AIM, Schattenkerk JKME, et al., and the Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327:1836–1841.
   PubMed Web of Science ®Google Scholar
• Schneider MME, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency vi-rus. J Infect Dis. 1995;171:1632–1636.
   PubMed Web of Science ®Google Scholar
• El-Sadr W, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in HIV infected individuals. Clin Infect Dis. 1999;29:775–783.
   PubMed Web of Science ®Google Scholar
• Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992;117:106–111.
   PubMed Web of Science ®Google Scholar
• Hardy WD, Feinberg J, Finkelstein DM, et al., for the AIDS Clinical Trials Group. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for second-ary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. N Engl J Med. 1992;327:1842–1848.
   PubMed Web of Science ®Google Scholar
• Leoung G, Standford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct challenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever [Abstract]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997. Abstract no. LB10.
   Google Scholar
• Para MF, Dohn M, Frame P, Becker S, Finkelstein D, Walawander A, for the ACTG 268 Study Team. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr. 2000;24:337–343.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Salazar A, Jiminez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in pa-tients infected with HIV. Ann Intern Med. 1995;122:755–761.
   PubMed Web of Science ®Google Scholar
• Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1995;20:531–541.
   PubMed Web of Science ®Google Scholar
• Chan C, Montaner J, LeFebyre EA, et al. Atovaquone suspension compared with aerosolized pentamidicine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus infected subsets intolerant of trimethoprim or sulfamethoxazole. J Infect Dis. 1999;180:369–376.
   PubMed Web of Science ®Google Scholar
• El-Sadr W, Murphy RL, Yurik RM, et al. Atovaquone com-pared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who can-not tolerate trimethoprim, sulfonamides, or both. N Engl J Med. 1998;339:1889–1895.
   PubMed Web of Science ®Google Scholar
• Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneu-monia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med. 1999;340:1301–1306.
   PubMed Web of Science ®Google Scholar
• Weverling GJ, Mocroft A, Ledergerber B, et al. Discon-tinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet. 1999;353:1293–1298.
   PubMed Web of Science ®Google Scholar
• Yangco BF, VonBargen JC, Moorman AC, Holmberg SD. Discontinuation of chemoprophylaxis for Pneumocystis carinii pneumonia in patients with HIV infection. Ann In-tern Med. 2000;132:201–205.
   Web of Science ®Google Scholar
• Schneider MME, Borleffs JCC, Stolk RP, Jaspers CAJJ, Hoepelman AIM. Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet. 1999;353:201–203.
   PubMed Web of Science ®Google Scholar
• Dworkin M, Hanson D, Jones J, Kaplan J, and the Adult/ Adolescent Spectrum of HIV Disease Project (ASD). Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T-Iym-phocyte counts above prophylaxis thresholds. J Infect Dis. 2000;182:611–615.
   PubMed Web of Science ®Google Scholar
• Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumo-nia and toxoplasmic encephalitis in human immunodefi-ciency virus type l-infected patients: The changes in op-portunistic prophylaxis study. J Infect Dis. 2000;181:1635–1642.
   PubMed Web of Science ®Google Scholar
• Lopez JC, Miro JM, Pena JM, Podzamczer D, and the GESIDA 04/98 Study Group. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after HAART in patients with HIV infection. N Engl J Med. 2001 ;344(3):159–167.
   PubMed Web of Science ®Google Scholar
• Furrer H, Opravil M, Rossi M, et al. Discontinuation of primary prophylaxis in HIV infected patients at high risk of pneumocystis pneumonia: A prospective multicentre study. AIDS. 2001;15:501–507.
   PubMed Web of Science ®Google Scholar
• Kirk O, Lundgren JD, Pederson C, Nielsen H, Gerstoft J. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS. 199913:1647-1651.
   PubMed Web of Science ®Google Scholar
• Soriano V, Dona C, Rodriguez-Rosado, et al. Discontinu-ation of secondary prophylaxis for opportunistic infec-tions in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2000;14:383–386.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, d'Arminio Monforte A, Schneider M, Lundgren, J. Discontinuation of second-ary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. New Engl J Med. 2001344: 168–174.
   Google Scholar
• CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR. 1995 44(No. RR–4).
   Google Scholar
• Department of Agriculture: http://www.foodsafety.gov.
   Google Scholar
• Miro JM, Podzamczer D, Pena JM, Alberdi J, et al. Dis-continuation of primary and secondary toxoplasma gondii prophylaxis is safe in HIV-1 infected patients after immunological recovery with HAART. Final results of the GESIDA 04/98 Study [Abstract]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society for Microbiology, 2000. Abstract No. L16
   Google Scholar
• Furrer H, Oparavil M, Bernasconi E, et al. Stopping pri-mary prophylaxis in HIV-1 infected patients at high risk of toxoplasma encephalitis. Lancet. 2000;355:2217–2218.
   PubMed Web of Science ®Google Scholar
• Katlama C, DeWit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996;22:268–275.
   PubMed Web of Science ®Google Scholar
• Dannemann B, McCutchan JA, Israelski D, et al. Treat-ment of toxoplasmic encephalitis in patients with AIDS: A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann In-tern Med. 1992;116:33–43.
   Web of Science ®Google Scholar
• Holmberg SD, Moorman AC, Von Bargen JC, et al. Pos-sible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. JAMA. 1998;279:384–386.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Zackin R, Feinberg J, et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS. 2000;14:2889–2893.
   PubMed Web of Science ®Google Scholar
• CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR. 2000;49 (No RR–6).
   Google Scholar
• CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. MMWR. 1998;47;(RR–20).
   Google Scholar
• Centers for Disease Control and Prevention. Notice to readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR. 2000;49:183–189.
   Google Scholar
• Masur H, and the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Com-plex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med. 1993;329:898–904.
   PubMed Web of Science ®Google Scholar
• Benson CA, Williams PL, Cohn DL, and the ACTG 196/ CPCRA 009 Study Team. Clarithromycin or Rifabutin alone or in combination for primary prophylaxis of Myco-bacterium avium complex disease in patients with AIDS: A randomized, double-blinded, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Commu-nity Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. 2000;181(4):1289–1297.
   PubMed Web of Science ®Google Scholar
• Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;335:384–391.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Dube MP, Settler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996;335:392–398.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Burman WJ, Grant LB, Malts JP, Hefner R, Crane L, Zeh D, Gallagher B, Mannheimer SB, Martinez A, Gordin F. Discontinuation of prophylaxis for mycobacte-rium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. New Engl J Med. 2000;342:1085–1092.
   PubMed Web of Science ®Google Scholar
• Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hefner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA. Dis-continuation of mycobacterium avium complex prophy-laxis in patients with antiretroviral therapy-induced in-creases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trial Group 362 Study Team. Ann Intern Med. 2000;133:493–503.
   PubMed Web of Science ®Google Scholar
• Furrer H, Rossi M, Telenti A, Lederberger B. Discontinu-ing or withholding primary prophylaxis against Mycobac-terium avium in patients on succesful antiretroviral com-bination therapy. AIDS. 2000;14:1409–1412.
   PubMed Web of Science ®Google Scholar
• Gordin F, Sullam P, Shafran S, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR. A randomized, pla-cebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of dissemi-nated infection with Mycobacterium avium complex (MAC). Clin Infect Dis. 1999 ;28(5):1080–1085.
   PubMed Web of Science ®Google Scholar
• Benson C, Williams P, Currier J, et al. ACTG223: An open, prospective, randomized study comparing efficacy and safety of clarithromycin (C) plus ethambutol (E), rifabutin (R), or both for treatment (Rx) of MAC disease in patients with AIDS [Abstract]. In: Program and abstracts 6th Con-ference on Retroviruses and Opportunistic Infections. Al-exandria, Virginia: Foundation for Retrovirology and Hu-man Health, 1999. Abstract no. 249.
   Google Scholar
• Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med. 1994;121:905–911.
   PubMed Web of Science ®Google Scholar
• Cohn DL, Fisher E, Peng GT, et al. A prospective random-ized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high dose clarithromycin. Clin Infect Dis. 1999;29(1):125–133.
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treat-ment of bacteremic Mycobacterium avium complex dis-ease in patients with HIV infection. AIDS. 1997;11:311–317.
   PubMed Web of Science ®Google Scholar
• Rabaud C, Jouan M, Mary-Krausse M, et al. Mycobacte-rium avium (MAC) infections during HAART era (1996–98) in HIV-infected French patients [Abstract 2054]. In: Pro-gram and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000; San Francisco, CA.
   Google Scholar
• Aberg JA, Yijko DM, Jacobson MA. Eradication of AIDS-related disseminated Mycobacterium avium complex in-fection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis. 1998;178:1446–1449.
   PubMed Web of Science ®Google Scholar
• Shafran SD, Gill MJ, Lajonde RG, et al. Successful dis-continuation of MAC therapy following effective HAART [Abstract 547]. In: Program and abstracts of the 8th Con-ference on Retroviruses and Opportunistic Infections, February 4–8, 2001; Chicago, IL.
   Google Scholar
• Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, Ernest JM. Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin. Obstet Gynecol. 1998;91:165–168.
   PubMed Web of Science ®Google Scholar
• Medical Economics Company, Inc. Physicians' Desk Ref-erence. 55th edition. Montvale, NJ: Medical Economics Company, Inc., 2001.
   Google Scholar
• Dworkin MS, Ward JW, Hanson DL, et al. Pneumococcal disease among HIV-infected persons: Incidence, risk fac-tors, and impact of vaccination. Clin Infect Dis. 2001 ;32(5):794–800.
   PubMed Web of Science ®Google Scholar
• Guerrero M, et al. Pneumonia in HIV-infected patients: A case-control survey of factors involved in risk and pre-vention. AIDS. 1999;13:1975–1981.
   Web of Science ®Google Scholar
• Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk fac-tors for pneumococcal disease in human immunodefi-ciency virus-infected patients. J Infect Dis. 1996;173:857–862.
   PubMed Web of Science ®Google Scholar
• CDC. Prevention of pneumococcal disease: recommen-dations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1997;46(No. RR–8).
   Google Scholar
• Breiman RF, Keller DW, Phelan MA. Evaluation of effec-tiveness of 23-valent pneumococcal capsular polysac-charide vaccine for HIV-infected patients. Arch Intern Med. 2000;160:2633–2638.
   PubMed Web of Science ®Google Scholar
• French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: Double-blind, randomised, and pla-cebo-controlled trial. Lancet. 2000;355:2106–2111.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended childhood immunization schedule - United States. MMWR. 200150: 7–11.
   Google Scholar
• American Academy of Pediatrics. Committee on Infec-tious Diseases. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (prevnar), pneu-mococcal polysaccharide vaccine, and antibiotic prophy-laxis. Pediatrics. 2000;106(2 Pt 1):362–366.
   PubMed Web of Science ®Google Scholar
• CDC. Preventing pneumococal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49(RR9):1–35.
   PubMedGoogle Scholar
• Spector SA, Gerber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med. 1994;331:1181–1187.
   PubMed Web of Science ®Google Scholar
• Powderly WG, Finkelstein DM, Feinberg J, et al. A ran-domized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995;332:700–705.
   PubMed Web of Science ®Google Scholar
• Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: A randomized, double-blind, placebo-con-trolled trial. Ann Intern Med. 1997;126:689–696.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998;27:1369–1375.
   PubMed Web of Science ®Google Scholar
• Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis. 1996;22:336–340.
   PubMed Web of Science ®Google Scholar
• Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: Report of an additional patient. Am J Med Genet. 1997;72:253–256.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical Company. Product information: Sporanox (itraconazole) oral solution. In: Medical Eco-nomics Company, Inc. Physicians' Desk Reference. 53rd edition. Montvale, NJ: Medical Economics Company, Inc., 1999:1441.
   Google Scholar
• Bozzette SA, Larsen R, Chiu J, et al. A controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodefi-ciency syndrome. N Engl J Med. 1991324: 580.
   Google Scholar
• Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired im-munodeficiency syndrome. N Engl J Med. 1992;326:793.
   PubMed Web of Science ®Google Scholar
• Saag MS, and the NIAID Mycoses Study Group. Com-parison of fluconazole versus itraconazole as mainte-nance therapy of AIDS-associated cyrptococcal meningi-tis. Clin Infect Dis. 1999;28(2):291–296.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Price RW, Heeren DM, et al. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy [Abstract 250]. In: Pro-gram and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000; San Francisco, CA.
   Google Scholar
• Mussini C, Cossarizza A, Pezzotti P, et al. Discontinuation or continuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with HAART [Abstrct 546]. In: Program and abstracts of the 8th Con-ference on Retroviruses and Opportunistic Infections, February 4–8, 2001; Chicago, IL.
   Google Scholar
• McKinsey DS, Wheat Li, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with ad-vanced human immunodeficiency virus infection: Ran-domized, placebo-controlled, double-blind study. Clin In-fect Dis. 1999;28:1049–1056.
   PubMed Web of Science ®Google Scholar
• Wheat J, Hefner R, Wulfsohn M, et al., and the NIASID Clinical Trials and Mycoses Study Group Collaborators. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syn-drome. Ann Intern Med. 1993;118:610–616.
   PubMed Web of Science ®Google Scholar
• Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Will-iams PL, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioido-mycosis. A randomized, double-blind trial. Ann Intern Med. 2000;133(9):676–686.
   PubMed Web of Science ®Google Scholar
• Spector SA, McKinley GF, Lalezari JFP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996;334:1491–1497.
   PubMed Web of Science ®Google Scholar
• Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS. 1998;12:269–277.
   PubMed Web of Science ®Google Scholar
• Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytome-galovirus disease in patients with advanced human im-munodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis. 1998;177:48–56.
   PubMed Web of Science ®Google Scholar
• Martin DF, Kupperman BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med. 1999;340:1063–1070.
   PubMed Web of Science ®Google Scholar
• Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 1995;333:615–620.
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS Research Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomega-lovirus Retinitis Trial. A randomized, controlled trial. Ann Intern Med. 1997;126:264–274.
   PubMed Web of Science ®Google Scholar
• Palestine AG, Polis MA, DeSmet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomega-lovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665–673.
   PubMed Web of Science ®Google Scholar
• Spector SA, Weingeist T, Pollard RE, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis. 1993;168:557–563.
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS in collaboration with the AIDS Clinical Trials Group: Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in pa-tients with AIDS. Arch Ophthalmol. 1996;114:23–33.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, España E, Muñoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Brit J Ophthalmol. 1994;78:120–124.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Carr LM, Doyle K, et al. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial. Ann Intern Med. 1997;126:264.
   PubMed Web of Science ®Google Scholar
• DeSmet MD, Meenken C, van den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocular Immunol Inflamm. 1999;7:189–198.
   PubMed Web of Science ®Google Scholar
• Kirsch LS, Arevelo JF, Chavez de la Paz E, et al. Infra-vitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with AIDS. Ophthalmology. 1995; 102:533–543.
   PubMed Web of Science ®Google Scholar
• Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology. 1998;105: 1404–1410.
   PubMed Web of Science ®Google Scholar
• Tural C, Romeu J, Sicrera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J In-fect Dis. 1998;177:1080–1083.
   PubMed Web of Science ®Google Scholar
• Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cy-tomegalovirus retinitis and elevated CD4+ counts. Oph-thalmology. 1998;105:1259–1264.
   PubMed Web of Science ®Google Scholar
• MacDonald JC, Torriani FJ, Morse, et al. Lack of reactiva-tion of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained el-evations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177:1182–1187.
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anti-cytomegalovirus therapy in persons with HIV in-fection and cytomegalovirus retinitis. JAMA. 1999;282: 1633–1637.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Bolton SG, Dunn JP, et al. Discontinuing anticytomegalovirus therapy in patients with immune re-constitution after combination antiretroviral therapy. Am J Ophthalmol. 1998;126:817–822.
   PubMed Web of Science ®Google Scholar
• Jouan M, Saves H, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV infected patients receving highly active antiretroviral therapy. Restimop Study Team. AIDS. 200115: 23–31.
   Google Scholar
• Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovi-rus (CMV) DNA load predicts CMV disease and survival in AIDS patients. JC/in Invest. 101:497–502.
   Google Scholar
• Salmon-Cerm D, Mazeron M-C, Caput S, et al. Plasma cytomegalovirus DNA, PP65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receving highly active antiretroviral therapy. AIDS. 2000;14:1042–1049.
   Web of Science ®Google Scholar
• Torriani FJ, Freeman WR, MacDonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS. 2000;14:173–180.
   PubMed Web of Science ®Google Scholar
• Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency vi-rus-infected men. J Infect Dis. 1998;178:1616–1622.
   PubMed Web of Science ®Google Scholar
• Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: A double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:21–28.
   PubMed Web of Science ®Google Scholar
• CDC. Pregnancy outcomes following systemic prenatal acyclovir exposure: June 1,1984-June 30,1993. MMWR. 1993;42:806–809.
   PubMedGoogle Scholar
• Jacobson LP, Jenkins FJ, Springer G, et al. Interaction of human immunodeficiency virus type 1 and human herp-esvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis. 2000;181:1940–1949.
   PubMed Web of Science ®Google Scholar
• Renwick N, Halaby T, Weverling GJ, et al. Seroconversion of human heresvirus 8 during HIV infection is highly pre-dictive of Kaposi's sarcoma. AIDS. 1998;12:2481–2488.
   PubMed Web of Science ®Google Scholar
• Martin JN, Ganem DE, Osmond DH, et al. Sexual trans-mission and the natural history of human herpsvirus 8 infection. N Engl J Med. 1998;338:948–954.
   PubMed Web of Science ®Google Scholar
• Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8. N Engl J Med. 2000;343:1369–1377.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Dollard SC, Smith OK, et al., HIV Epidemiol-ogy Research Study Group. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection. N Engl J Med. 2001;344:637–643.
   PubMed Web of Science ®Google Scholar
• Whitley D, Smith NA, Mathew S, et al. Human herpesvirus 8 seroepidemiology among women and detection in the genital tract of seropositive women. J Infect Dis. 1999; 179:254–256.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study. JAMA. 1999;23:2220–2226.
   Web of Science ®Google Scholar
• Bourboulia D, Whitby D, Boshoff C, et al. Serologic evi-dence of mother to child transmission of Kaposi-sar-coma-associated herpesvirus infection. JAMA. 1998;280: 31–32.
   PubMed Web of Science ®Google Scholar
• He J, Bhat G, Kankasa C, et al. Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS. J Infect Dis. 1998;178:787–790.
   Web of Science ®Google Scholar
• Sitas F, Newton R, Boshoff C. Increasing probability of mother to child transmission of HHV-8 with increasing maternal antibody titer for HHV-8. N Engl J Med. 1999;340:1923.
   PubMed Web of Science ®Google Scholar
• Plancoulaine S, Abel L, van Beveren M, et al. Human herpesvirus 8 transmission from mother to child and be-tween siblings in an endemic population. Lancet. 2000;356:1062–1065.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cer-vical cytology. JAMA. 1994;271:1866–1869.
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822–1829.
   PubMed Web of Science ®Google Scholar
• Maiman M, Watts DH, Andersen J, et al. Vaginal 5-fluo-rouracil for high grade cervical dysplasia in HIV-infection: A randomized trial. Obstet GynecoL 1999;94(6):954–961.
   PubMed Web of Science ®Google Scholar
• CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998;47(No. RR–19).
   Google Scholar
• Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis B and C virus infection. JAMA. 2000;283:74–80.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425–1431.
   PubMed Web of Science ®Google Scholar
• Eyster ME, Dimondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter He-mophilia Cohort Study. J Acquir Immune Defic Syndr. 1993;6:602–610.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425–1431.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Shih JW, Alter HG, et al. Effect of HIV infec-tion on hepatitis C virus infection among injection drug users. J Infect Dis. 1996;174:690–695.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy [letter]. AIDS. 1998;12:1256.
   PubMed Web of Science ®Google Scholar
• Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or Hepatitis C virus infection is a risk factor for severe he-patic cytolysis after initiation of a protease containing antiretroviral regimen in human immunodeficiency virus infected patients. The APROCO Study Group. Antimicrob Agents Chemother. 2000;44:3451–3455.
   PubMed Web of Science ®Google Scholar
• Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon in chronic hepatitis C. Ann Intern Med. 1996;124:1058–1060.
   PubMed Web of Science ®Google Scholar
• Mast EE, Alter MJ. Hepatitis C. Semin Pediatr Infect Dis. 1997;8:17–22.
   Google Scholar